{"id":387347,"date":"2020-11-24T05:33:20","date_gmt":"2020-11-24T10:33:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387347"},"modified":"2020-11-24T05:33:20","modified_gmt":"2020-11-24T10:33:20","slug":"aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/","title":{"rendered":"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN JOSE, Calif.<\/span>, <span class=\"xn-chron\">Nov. 24, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute &#8220;Fireside Chat Forum,&#8221; with its five covering analysts will be held on <span class=\"xn-chron\">December 4<\/span><sup>th<\/sup>, 2020 at <span class=\"xn-chron\">11:00AM EST<\/span>. This virtual event is intended to provide a 2021 preview and plans for the Company&#8217;s lead clinical programs, COVID-19 mAb programs, and \u028ePEX<span>\u2122<\/span>, its novel antibody discovery platform technology.\u00a0 <\/p>\n<p>This uniquely formatted event will feature all of the Company&#8217;s covering analysts, <span class=\"xn-person\">Louise Chen<\/span> (Cantor Fitzgerald), <span class=\"xn-person\">Vernon Bernardino<\/span> (H.C. Wainwright), <span class=\"xn-person\">Jason McCarthy<\/span> (Maxim Group), <span class=\"xn-person\">Jonathan Aschoff<\/span> (Roth Capital),\u00a0and <span class=\"xn-person\">Carl Byrnes<\/span> (Northland Securities) who will lead topic specific discussions with management to preview the year ahead (2021) for the following assets:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>AR-301:<\/b>\u00a0Currently enrolling a Phase 3 global clinical trial in patients with ventilator associated pneumonia (VAP) including patients who presented with VAP secondary to ventilator placement for COVID-19. Interim data expected in 1H 2021; full data in YE 2021. <\/li>\n<li>\n          <b>AR-501: <\/b>On-going Phase 2 clinical trial for treating chronic lung infections in patients with cystic fibrosis (CF). Study completion expected in 2H 2021. <\/li>\n<li>\n          <b>\u028ePEX<span>\u2122<\/span> Technology Platform: <\/b>Rapidly identifies rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture mAbs for therapeutic treatment of critical infections. <\/li>\n<li>\n          <b>COVID-19 (AR-711 &amp; 701): <\/b>Developing inhaled, self-administered, at-home treatment for mild-to-moderate condition (AR-711). A clinical Phase 1\/2 study to be launched in 1H 2021. Continuing characterization of monoclonal antibody cocktail (AR-701) for intravenous inpatient treatment for moderate-severe indications. <\/li>\n<\/ul>\n<p>&#8220;It is a pleasure to host this forum as it will offer efficient, yet comprehensive perspectives from leading Wall Street analysts on our programs and cutting-edge technology platform, especially in light of the current pandemic and on-going challenges facing the medical and science communities around emerging life-threatening infections,&#8221; commented <span class=\"xn-person\">Vu Truong<\/span>, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.<\/p>\n<p>Additional details and registration can be accessed with <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2991210-1&amp;h=422654434&amp;u=https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_fuBz0MReStOQ4SbJX3Lg3Q&amp;a=this+link\" rel=\"nofollow noopener noreferrer\">this link<\/a> or by visiting Aridis&#8217; website, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2991210-1&amp;h=4065415697&amp;u=https%3A%2F%2Finvestors.aridispharma.com%2Fevents&amp;a=https%3A%2F%2Finvestors.aridispharma.com%2Fevents\" rel=\"nofollow noopener noreferrer\">https:\/\/investors.aridispharma.com\/events<\/a>.<\/p>\n<p>\n        <b>About Aridis Pharmaceuticals, Inc. <br \/><\/b>Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary \u028ePEX<span>\u2122<\/span> and MabIgX\u00ae technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor&#8217;s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.<\/p>\n<p>The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company&#8217;s pipeline is highlighted below:<\/p>\n<p>\n        <b>Aridis&#8217;\u00a0Pipeline <br \/><\/b><br \/>\n        <b>AR-301<\/b>\u00a0(VAP).\u00a0AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive\u00a0<i>Staphylococcus aureus<\/i> (<i>S. aureus)\u00a0<\/i>alpha-toxin in VAP\u00a0patients.<\/p>\n<p>\n        <b>AR-101<\/b>\u00a0(HAP).\u00a0AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting\u00a0<i>Pseudomonas aeruginosa<\/i> (<i>P. aeruginosa)\u00a0<\/i>liposaccharides serotype O11, which accounts for approximately 22% of all\u00a0<i>P. aeruginosa\u00a0<\/i>hospital acquired pneumonia cases worldwide. <\/p>\n<p>\n        <b>AR-501<\/b>\u00a0(cystic fibrosis).\u00a0AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients.\u00a0 This program is currently in a Phase 1\/2a clinical study in healthy volunteers and CF patients.<\/p>\n<p>\n        <b>AR-401<\/b>\u00a0(blood stream infections).\u00a0AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative\u00a0<i>Acinetobacter baumannii<\/i>.<\/p>\n<p>\n        <b>AR-701<\/b> (COVID-19). AR-701 is a cocktail of fully human mAbs discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins of the SARS-CoV-2 virus. <\/p>\n<p>\n        <b>AR-711<\/b> (COVID-19). AR-711 is an in-licensed mAb that is directed against the receptor binding domain of the SARS-CoV-2 virus. The agent has the potential to be delivered both intravenously and by inhalation using a nebulizer.<\/p>\n<p>\n        <b>AR-201\u00a0<\/b>(RSV infection). AR-201 is a fully human IgG1 mAb out-licensed preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).<\/p>\n<p>For additional information on Aridis Pharmaceuticals, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2991210-1&amp;h=487947228&amp;u=https%3A%2F%2Faridispharma.com%2F&amp;a=https%3A%2F%2Faridispharma.com%2F\" rel=\"nofollow noopener noreferrer\">https:\/\/aridispharma.com\/<\/a>. <\/p>\n<p>\n        <b>Forward-Looking Statements <br \/><\/b>Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties.\u00a0 These statements may be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;forecast,&#8221; &#8220;estimated&#8221; and &#8220;intend&#8221; or other similar terms or expressions that concern Aridis&#8217; expectations, strategy, plans or intentions. These forward-looking statements are based on Aridis&#8217; current expectations and actual results could differ materially. \u00a0There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. \u00a0These factors include, but are not limited to, the need for additional financing, the timing of regulatory submissions, Aridis&#8217; ability to obtain and maintain regulatory approval of its existing product candidates and any other product candidates it may develop, approvals for clinical trials may be delayed or withheld by regulatory agencies, risks relating to the timing and costs of clinical trials, risks associated with obtaining funding from third parties, management and employee operations and execution risks, loss of key personnel, competition, risks related to market acceptance of products, intellectual property risks, risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our\u00a0financial condition and increase our costs and expenses, risks associated with the uncertainty of future financial results, Aridis&#8217; ability to attract collaborators and partners and risks associated with Aridis&#8217; reliance on third party organizations.\u00a0 While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption &#8220;Risk Factors&#8221; in Aridis&#8217; 10-K for the year ended <span class=\"xn-chron\">December 31, 2019<\/span> and Aridis&#8217; other filings made with the Securities and Exchange Commission.\u00a0Forward-looking statements included herein are made as of the date hereof, and Aridis does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.<\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<p>Investor Relations <br \/><span class=\"xn-person\">Jason Wong<\/span><br \/>Blueprint Life Science Group <br \/><a target=\"_blank\" href=\"mailto:jwong@bplifescience.com\" rel=\"nofollow noopener noreferrer\">jwong@bplifescience.com<\/a><br \/>(415) 375-3340 Ext. 4<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3333\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.jpg\" title=\"Aridis Pharmaceuticals, Inc. Logo (PRNewsfoto\/Aridis Pharmaceuticals, Inc.)\" alt=\"Aridis Pharmaceuticals, Inc. Logo (PRNewsfoto\/Aridis Pharmaceuticals, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF01421&amp;sd=2020-11-24\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020-301179175.html\">http:\/\/www.prnewswire.com\/news-releases\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020-301179175.html<\/a><\/p>\n<p>SOURCE  Aridis Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF01421&amp;Transmission_Id=202011240530PR_NEWS_USPR_____SF01421&amp;DateId=20201124\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN JOSE, Calif., Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute &#8220;Fireside Chat Forum,&#8221; with its five covering analysts will be held on December 4th, 2020 at 11:00AM EST. This virtual event is intended to provide a 2021 preview and plans for the Company&#8217;s lead clinical programs, COVID-19 mAb programs, and \u028ePEX\u2122, its novel antibody discovery platform technology.\u00a0 This uniquely formatted event will feature all of the Company&#8217;s covering analysts, Louise Chen (Cantor Fitzgerald), Vernon Bernardino (H.C. Wainwright), Jason McCarthy (Maxim Group), Jonathan Aschoff (Roth Capital),\u00a0and Carl Byrnes (Northland Securities) who will lead &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387347","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN JOSE, Calif., Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute &#8220;Fireside Chat Forum,&#8221; with its five covering analysts will be held on December 4th, 2020 at 11:00AM EST. This virtual event is intended to provide a 2021 preview and plans for the Company&#8217;s lead clinical programs, COVID-19 mAb programs, and \u028ePEX\u2122, its novel antibody discovery platform technology.\u00a0 This uniquely formatted event will feature all of the Company&#8217;s covering analysts, Louise Chen (Cantor Fitzgerald), Vernon Bernardino (H.C. Wainwright), Jason McCarthy (Maxim Group), Jonathan Aschoff (Roth Capital),\u00a0and Carl Byrnes (Northland Securities) who will lead &hellip; Continue reading &quot;Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T10:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020\",\"datePublished\":\"2020-11-24T10:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/\"},\"wordCount\":1186,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780881\\\/Aridis_Pharmaceuticals_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/\",\"name\":\"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780881\\\/Aridis_Pharmaceuticals_Inc_Logo.jpg\",\"datePublished\":\"2020-11-24T10:33:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780881\\\/Aridis_Pharmaceuticals_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780881\\\/Aridis_Pharmaceuticals_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/","og_locale":"en_US","og_type":"article","og_title":"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 - Market Newsdesk","og_description":"PR Newswire SAN JOSE, Calif., Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute &#8220;Fireside Chat Forum,&#8221; with its five covering analysts will be held on December 4th, 2020 at 11:00AM EST. This virtual event is intended to provide a 2021 preview and plans for the Company&#8217;s lead clinical programs, COVID-19 mAb programs, and \u028ePEX\u2122, its novel antibody discovery platform technology.\u00a0 This uniquely formatted event will feature all of the Company&#8217;s covering analysts, Louise Chen (Cantor Fitzgerald), Vernon Bernardino (H.C. Wainwright), Jason McCarthy (Maxim Group), Jonathan Aschoff (Roth Capital),\u00a0and Carl Byrnes (Northland Securities) who will lead &hellip; Continue reading \"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T10:33:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020","datePublished":"2020-11-24T10:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/"},"wordCount":1186,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/","name":"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.jpg","datePublished":"2020-11-24T10:33:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/780881\/Aridis_Pharmaceuticals_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook-for-its-lead-programs-and-novel-mab-discovery-platform-on-december-4th-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387347"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387347\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}